MXPA04005784A - 2-fenilbenzofuranos sustituidos como agentes estrogenitos. - Google Patents

2-fenilbenzofuranos sustituidos como agentes estrogenitos.

Info

Publication number
MXPA04005784A
MXPA04005784A MXPA04005784A MXPA04005784A MXPA04005784A MX PA04005784 A MXPA04005784 A MX PA04005784A MX PA04005784 A MXPA04005784 A MX PA04005784A MX PA04005784 A MXPA04005784 A MX PA04005784A MX PA04005784 A MXPA04005784 A MX PA04005784A
Authority
MX
Mexico
Prior art keywords
substituted
estrogenic agents
phenyl benzofurans
benzofurans
phenyl
Prior art date
Application number
MXPA04005784A
Other languages
English (en)
Inventor
J Unwalla Rayomand
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04005784A publication Critical patent/MXPA04005784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Esta invencion proporciona moduladores del receptor de estrogeno de formula I que tienen la estructura (I) en donde R, R??, A, A??, X, Y e Y son como se define en la especificacion, o una sal farmaceuticamente aceptable del mismo.
MXPA04005784A 2001-12-18 2002-12-17 2-fenilbenzofuranos sustituidos como agentes estrogenitos. MXPA04005784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34163801P 2001-12-18 2001-12-18
PCT/US2002/040224 WO2003051860A2 (en) 2001-12-18 2002-12-17 Substituted 2-phenyl benzofurans as estrogenic agents

Publications (1)

Publication Number Publication Date
MXPA04005784A true MXPA04005784A (es) 2004-09-13

Family

ID=23338402

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005784A MXPA04005784A (es) 2001-12-18 2002-12-17 2-fenilbenzofuranos sustituidos como agentes estrogenitos.

Country Status (13)

Country Link
US (3) US6774248B2 (es)
EP (1) EP1458700B1 (es)
JP (1) JP2006506315A (es)
CN (1) CN1606551A (es)
AR (1) AR037883A1 (es)
AT (1) ATE416170T1 (es)
AU (1) AU2002366356A1 (es)
BR (1) BR0215058A (es)
CA (1) CA2470352A1 (es)
DE (1) DE60230187D1 (es)
MX (1) MXPA04005784A (es)
TW (1) TW200301106A (es)
WO (1) WO2003051860A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
TW200409759A (en) 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
PL1633699T3 (pl) * 2003-05-16 2007-05-31 Wyeth Corp Pochodne oksymów arylo-karbaldehydów i ich zastosowanie jako środków estrogennych
WO2005011670A1 (en) 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
CA2570518A1 (en) * 2004-07-01 2006-01-19 Wyeth Tetracyclic compounds as estrogen ligands
BRPI0519111A2 (pt) * 2004-12-17 2008-12-23 Wyeth Corp mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta
AR059574A1 (es) * 2006-02-14 2008-04-16 Wyeth Corp Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta
EA019833B1 (ru) 2007-01-22 2014-06-30 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CA2676553A1 (en) * 2007-01-31 2008-08-07 Wyeth Use of er.beta. selective ligands for treating acute lung injuries
GB0806656D0 (en) * 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
CN103079558A (zh) * 2010-04-05 2013-05-01 满康德股份有限公司 IRE-1α抑制剂
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CN103724306B (zh) * 2014-01-24 2015-03-11 温州大学 一种苯并呋喃衍生物的制备方法
EP3374354B1 (en) * 2015-11-11 2022-09-28 Ambient Photonics, Inc. Benzofuran derivatives for the treatment of cns and other disorders
US11673866B2 (en) 2018-05-23 2023-06-13 The Board Of Trustees Of The University Of Illinois Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
CA3106199A1 (en) 2018-07-10 2020-01-16 Ambient Photonics, Inc. Solar cell dyes for copper redox based dye sensitized solar cells and combinations thereof
CN108997282B (zh) * 2018-07-25 2022-04-29 安徽工程大学 具有α-葡萄糖苷酶抑制活性的芳基苯并呋喃类衍生物
CN109030681B (zh) * 2018-09-20 2021-10-01 广西壮族自治区药用植物园 鉴定山豆根真伪的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087638A (en) 1984-06-20 1992-02-11 Merck Frosst Canada, Inc. Benzofuran derivatives
US4863958A (en) 1984-06-20 1989-09-05 Merck Frosst Canada, Inc. Benzofuran derivatives useful as inhibitors of mammalian leukotriene biosynthesis
US5705507A (en) 1995-03-10 1998-01-06 Eli Lilly And Company Aplha-substituted-3-benzyl-benzofurans
US20020099086A1 (en) 1998-07-31 2002-07-25 Proteome Sciences Plc Use of extracts from aristolochia in the treatment of AIDS
PT2264018E (pt) 2000-08-24 2015-06-03 Univ Pittsburgh Derivados de tioflavina para uso no diagnóstico da doença de alzheimer

Also Published As

Publication number Publication date
US7022733B2 (en) 2006-04-04
WO2003051860A3 (en) 2003-12-04
AU2002366356A1 (en) 2003-06-30
US20030171428A1 (en) 2003-09-11
ATE416170T1 (de) 2008-12-15
CN1606551A (zh) 2005-04-13
BR0215058A (pt) 2006-06-06
AR037883A1 (es) 2004-12-09
DE60230187D1 (de) 2009-01-15
US20050038107A1 (en) 2005-02-17
JP2006506315A (ja) 2006-02-23
WO2003051860A2 (en) 2003-06-26
US6774248B2 (en) 2004-08-10
EP1458700B1 (en) 2008-12-03
CA2470352A1 (en) 2003-06-26
EP1458700A2 (en) 2004-09-22
US20060074128A1 (en) 2006-04-06
TW200301106A (en) 2003-07-01

Similar Documents

Publication Publication Date Title
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
UA83620C2 (ru) Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003051805A3 (en) Substituted phenyl naphthalenes as estrogenic agents
PL1653947T3 (pl) Pochodne oksymów (4-hydroksyfenylo)-1H-indolo-3-karbaldehydów jako środki estrogenne
MXPA05012249A (es) Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos.
PL1620392T3 (pl) Oksymowe pochodne hydroksy-bifenylo-karbaldehydu i ich zastosowania jako środków estrogennych
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
IL155236A0 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
GB9929552D0 (en) Compounds
AP2004003007A0 (en) 3-Azabicyclo (3.1.0) hexane derivatives as oploid receptor antagonists.
GB0114185D0 (en) Compounds
AP2002002616A0 (en) Antidibetic agents
AU1366802A (en) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives
DE60006825D1 (de) Serotonerge benzofurane
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
DE60015146D1 (en) Serotonerge benzothiophene
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
PL341487A1 (en) Plater's wedge
HK1038922A1 (en) N-substituted indolines as estrogenic agents n.
AU2002345403A1 (en) Novel 2,4-difluorobenzamide derivatives as antiviral agents
MA24881A1 (fr) Couscous d'orge

Legal Events

Date Code Title Description
FG Grant or registration